Eikon Therapeutics/$EIKN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eikon Therapeutics
Eikon Therapeutics, founded in 2019 and headquartered in Hayward, California, is a biotechnology company specializing in the development of therapies for serious illnesses, with a primary focus on oncology. The company employs proprietary super-resolution microscopy and single-molecule tracking technologies to observe protein dynamics in living cells, aiming to accelerate drug discovery and development. Eikon's clinical pipeline includes EIK1001, a co-agonist of toll-like receptors 7 and 8 in Phase III trials for advanced melanoma, and EIK1003, a selective PARP1 inhibitor in Phase I trials for various cancers. The company has secured over $1.1 billion in private funding to support its research and development efforts.
Ticker
$EIKN
Sector
Primary listing
Employees
-
Headquarters
Website
EIKN Metrics
BasicAdvanced
$858M
-
-$113.66
-
-
Price and volume
Market cap
$858M
Financial strength
Current ratio
8.796
Quick ratio
8.364
Long term debt to equity
66.357
Total debt to equity
67.409
Interest coverage (TTM)
-335.47%
Profitability
EBITDA (TTM)
-281.986
Management effectiveness
Valuation
Price to book
-0.06
Price to tangible book (TTM)
-0.06
Price to free cash flow (TTM)
-0.194
Free cash flow yield (TTM)
-514.22%
Free cash flow per share (TTM)
-92.555
Growth
EIKN Financial Performance
Revenues and expenses
EIKN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eikon Therapeutics stock?
Eikon Therapeutics (EIKN) has a market cap of $858M as of February 06, 2026.
What is the P/E ratio for Eikon Therapeutics stock?
The price to earnings (P/E) ratio for Eikon Therapeutics (EIKN) stock is 0 as of February 06, 2026.
Does Eikon Therapeutics stock pay dividends?
No, Eikon Therapeutics (EIKN) stock does not pay dividends to its shareholders as of February 06, 2026.
When is the next Eikon Therapeutics dividend payment date?
Eikon Therapeutics (EIKN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eikon Therapeutics?
Eikon Therapeutics (EIKN) does not currently have a Beta indicator.